Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study

BackgroundAlthough several clinical studies have laid the foundation for the adjuvant application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), some questions remain unresolved. This real-world study aimed to address questions such as the effect of adjuvant chemotherapy...

Full description

Bibliographic Details
Main Authors: Jun-Feng Liu, Xu-Sheng Sun, Jin-Huan Yin, Xi-E Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
adjuvant treatment
EGFR-TKI
non-small cell lung cancer
EGFR-mutation positive
adjuvant chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1132854/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1132854/full

Similar Items